55.13 USD
▲+0.30+2.74%
盘后 53.72 +0.11%
2026-08-03
市值
$1.63B
市盈率
—
EPS
-0.95
股息率
—
52 周区间
17.11 – 73.30
成交量
417.43K
Beta
0.38
目标价
87.09
52W 低 17.1152W 高 73.30
价格走势
公司简介
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid ...